Introduction
Histiocytosis syndromes of childhood constitute a diverse group of disorders and are grouped together because of the common feature of proliferation of cells of monocytemacrophage system of bone marrow origin. It is classified on the basis of histopathological findings into two common forms -"Langerhans cell histiocytosis" (LCH) and "hemophagocytic lymphohistiocytosis." LCH was previously known as "Histiocytosis X" which included eosinophilic granuloma, Hand-Schuller-Christian disease, and Letterer-Siwe disease.
The hallmark of LCH is the presence of clonal proliferation of cells of the monocyte lineage containing the characteristic electron microscopic finding of Langerhans cells. This is a tennis racket-shaped bilamellar granule called Birbeck granule, seen in the cytoplasm of lesional cell in LCH. This granule expresses Langerin CD 207 and shows CD1a positivity which is now used for the definitive diagnosis of LCH, and the demonstration of Birbeck granule is no longer necessary to establish diagnosis.
LCH remains a difficult-to-diagnose and a poorly understood disease. It has heterogeneous clinical presentation ranging from unifocal bony involvement to disseminated disease with life-threatening complications. The outcome of the disease also varies from spontaneous resolution to a progressive multisystem (MS) disorder with organ dysfunction. We present our experience of diagnosing and managing children with LCH over a decade at a single institution.
Materials and Methods
A total of 28 children of LCH, managed in a pediatric oncology unit in North India from January 2006 to January 2016, were retrospectively analyzed.
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Definition of response criteria
There are three categories of response: 
Results
Age of the patients ranged between 5 months and 9 years, with a mean of 3½ years. Five patients (17.8%) were equal to or less than 1 year of age at presentation. The M: F ratio was 3:1.
SS, unifocal and multifocal bone diseases were seen in nine (32.1%) and two (7.1%) cases, respectively. Disseminated disease without risk organ involvement was seen in six (21.1%), whereas disseminated disease with risk organ involvement was seen in 11 (39.3%) of cases.
The presenting signs and symptoms are summarized in Table 1 where bony involvement was the most common presentation (67.8%) followed by hepatosplenomegaly and/or lymphadenopathy in 42.8% each. Lung involvement was seen in three (10.7%) patients, whereas another three (10.7%) had central diabetes insipidus. One of these patients presented with only central diabetes insipidus initially and developed scalp swelling 6 months later. Seven children (25%) had skin and/or nail involvement in the form of seborrhoeic dermatitis and dystrophic nails. The distribution of bony lesions is summarized in Table 2 . Nineteen (67.8%) children had bony lesions, out of which 16 (88.8%) had skull involvement. Vertebrae was the next common site (26.3%) followed by upper-limb bones, lower-limb bones, and pelvis (15.7% each).
During follow-up, 17 (60.7%) children were in complete remission (CR) though five (17.8%) of them relapsed, but achieved second remission and continue to be in CR. Two (7.1%) patients achieved remission, but were lost to follow-up after 1 year of treatment. Six (21.4%) children had progressive disease, of which four expired and two abandoned treatment. Two (10.7%) patients refused treatment initiation, whereas one patient chose to be treated at another center. All deaths occurred in patients with MS disease. None of the patients underwent stem cell transplantation during the study period.
Discussion
LCH is an uncommon and poorly understood disease of variable presentation. Patients with LCH can present to physicians of different specialties with variable complaints. They can present to an orthodontist with floating teeth, [2] to a dermatologist with skin lesions, [3] to an orthopedic surgeon with bony lesions, or to a pediatric surgeon with scalp swelling. [4] One of our patients had only skin involvement and presented to the dermatologist. Diagnosis was established after a skin biopsy. Similarly, another child presented to dental outpatient department with loose teeth, in which an X-ray of the jaw showed several floating teeth, giving rise to the suspicion of LCH. A high index of suspicion is required to make an accurate diagnosis.
LCH can occur at any age, but younger age is more common. In our study, the mean age was 3½ years, and approximately one-fifth of the patients were infants. There was a male predominance with a M/F ratio of 3:1. MS disease which constituted the bulk of the disease was found in 17 (60.7%) cases. Another study has also reported the same in a tertiary care center. [5] Bony involvement was the most common presentation followed by fever and lymphadenopathy. Similar findings have been reported in other studies. [6, 7] Pulmonary involvement was seen in 10.7% of our patients, whereas another study [8] reported pulmonary LCH in 25% of patients. Three (10.7%) patients had diabetes insipidus at the time of diagnosis. One of these patients presented with only diabetes insipidus and developed a boggy swelling over the scalp 6 months later which turned out to be LCH. In a series of forty cases from another center, [6] three patients (7.5%) had diabetes insipidus.
LCH has a very variable course akin to its presentation. The disease may have a very benign course requiring minimal treatment or may run a malignant course requiring second-line treatment. Nonresponding patients may require stem cell transplantation. For past several decades, it has been debated if the disease is primarily an immune dysregulatory disorder or a neoplasm. Over the years, evidence has provided the view that LCH is a neoplasm, and consequently recurrent episodes of the disease should be called relapse rather than reactivation. In our study also, several patients had relapse of the disease and achieved second CR. However, one-fifth of the patients had a progressive course, of which many succumbed to the disease and few abandoned treatment in view of poor response. All these patients had MS disease with or without risk organ involvement. Another study has also reported that event-free survival for MS-LCH with risk organ involvement is suboptimal in Indian patients. [9] A couple of recent studies have reported good results in relapsed/refractory LCH and given new hope in this difficult subset of patients. However, patients with refractory/progressive disease in our series had adverse outcome. [10] [11] [12] Conclusion LCH is a rare disease and should be considered in patients with unexplained clinical manifestations of liver, lung, CNS, skin, and bone. Its myriad manifestations may further complicate and delay the diagnosis. Treatment and prognosis depends on the extent of the disease. Early recognition, diagnosis, and multidisciplinary approach can improve the outcome.
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There are no conflicts of interest. Dear Editor, Salivary gland tumors are rare and constitute about 5%-6% of all head-and-neck cancer. [1] In view of their rarity, no randomized controlled trials are available to guide treatment decisions. However based on various prospective and retrospective data, surgery is the cornerstone of treatment in localized tumors. Studies comparing primary radiotherapy to surgery have consistently shown superior survival with surgery. [2] Unresectable or technically unresectable tumors are treated with radical radiotherapy and have inferior outcomes when compared to resectable tumors. In oral cavity cancers, neoadjuvant chemotherapy has shown to downstage technically unresectable tumors to resectable tumors in around 40% of patients, almost doubling their overall survival. [3] Similar strategy has never been tried in salivary gland tumors. We report here a case of technically unresectable carcinoma of parotid where the use of neoadjuvant chemotherapy resulted in downstaging of the tumor leading to its successful surgical resection.
A 52-year-male patient presented with the complaints of swelling over the right parotid region with facial weakness for 2 years. Fine-needle aspiration cytology from the swelling was suggestive of high-grade adenocarcinoma of the parotid. His positron-emission tomography (PET) scan image showed fluorodeoxyglucose (FDG)-avid soft-tissue mass with necrotic areas involving superficial and deep lobes of the right parotid gland (4.2 cm × 4.2 cm, maximum standardized uptake value [SUVmax] 22.87) and FDG-avid multiple necrotic right level II, III, and IB nodes (largest 2.5 cm, SUVmax 16.91). His tumor staging was cT4aN2bM0.
The patient was seen in multidisciplinary clinic and in view of extensive disease, abutting mastoid, and involving stylomastoid foramen and he was deemed technically unresectable. He was then planned for neoadjuvant chemotherapy and received paclitaxel (175 mg/m 2 ) and cisplatin (75 mg/m 2 ), every 3 weeks for three cycles. Response assessment with PET scan showed significant regression in the parotid mass which now measured about 1.2 cm × 1.3 cm with SUVmax 3.72 and complete resolution of cervical adenopathy. He then underwent right parotidectomy with modified neck dissection [ Figure 1 ]. Postsurgery histopathology report showed no residual tumor suggestive of complete pathological response.
Patient has been regular follow-up since then and is disease-free at 2 years.
In our center, we have used neoadjuvant chemotherapy in technically unresectable advanced head-and-neck malignancies. This approach has helped downstage the tumor making them amenable for surgical resection in a significant proportion of patients. [3] Although the definitive treatment for parotid gland tumors remains surgery, [4] neoadjuvant chemotherapy has been tried in these tumors. However, there is scarce literature regarding neoadjuvant chemotherapy in salivary gland tumors. [5] Our case report has shown that neoadjuvant chemotherapy can be considered in advanced technically unresectable parotid gland tumors to make them amenable to resection.
